Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482807 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00482807 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 9 participants.
The verdict
NCT00482807, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high- dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with chemotherapy and hormone therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when given together with intensity-modulated radiation therapy and hormone therapy in treating patients with high-risk locally advanced prostate cancer with pelvic lymph node metastasis.
Interventions
- DRUG docetaxel
- DRUG goserelin
- RADIATION intensity-modulated radiation therapy
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-08-31 |
| Est. Completion | 2010-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482807
The ClinicalTrials.gov registry entry for NCT00482807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which docetaxel is the first listed.
NCT00482807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482807 about?
NCT00482807 is a clinical study titled "Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer". RATIONALE: Specialized radiation therapy that delivers a high- dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT00482807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-08-31. Estimated completion is 2010-03-09.
What interventions are being tested in trial NCT00482807?
The interventions under investigation include: docetaxel (DRUG), goserelin (DRUG), intensity-modulated radiation therapy (RADIATION), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00482807?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.